Value of reduced glomerular filtration rate assessment with cardiometabolic index: insights from a population-based Chinese cohort

Hao-Yu Wang†, Wen-Rui Shi†, Xin Yi², Shu-Ze Wang³, Si-Yuan Luan⁴ and Ying-Xian Sun*†

Abstract

Background: Recent studies have suggested that cardiometabolic index (CMI), a novel estimate of visceral adipose tissue, could be of use in the evaluation of cardiovascular risk factors. However, the potential utility and clinical significance of CMI in the detection of reduced estimated glomerular filtration rate (eGFR) remains uncertain. The purpose of this study was to investigate the usefulness of CMI in assessing reduced eGFR in the general Chinese population.

Methods: This cross-sectional analysis included 11,578 participants (mean age: 53.8 years, 53.7% females) from Northeast China Rural Cardiovascular Health Study (NCRCHS) of general Chinese population (data collected from January 2013 to August 2013). CMI was calculated by triglyceride to high density lipoprotein cholesterol ratio multiply waist-to-height ratio. Reduced eGFR was defined as eGFR< 60 ml/min per 1.73m². Multivariate regressions were performed to determine CMI’s association with eGFR value and eGFR reduction, ROC analyses were employed to investigate CMI’s discriminating ability for decreased eGFR.

Results: The prevalence of reduced eGFR was 1.7% in males and 2.5% in females. CMI was notably more adverse in reduced eGFR groups, regardless of genders. In fully adjusted multivariate linear models, each 1 SD increment of CMI caused 3.150 ml/min per 1.73m² and 2.411 ml/min per 1.73m² loss of eGFR before CMI reached 1.210 and 1.520 in males and females, respectively. In logistic regression analyses, per 1 SD increase of CMI brought 51.6% additional risk of reduced eGFR in males while caused 1.347 times of risk in females. After divided into quartiles, people in the top quartile of CMI had higher adjusted ORs of having reduced eGFR, with ORs of 4.227 (1.681, 10.627) and 3.442 (1.685–7.031) for males and females respectively. AUC of CMI was revealed to be 0.633 (0.620–0.646) in males and 0.684 (0.672–0.695) in females.

Conclusions: Higher CMI was independently associated with greater burden of reduced eGFR, highlighting VAT distribution and dysfunction as a potential mechanism underlying the association of obesity with kidney damage and adverse cardiovascular outcomes. The findings from this study provided important insights regarding the potential usefulness and clinical relevance of CMI in the detection of reduced eGFR among general Chinese population.

Keywords: Cardiometabolic index, Dyslipidemia, Obesity, Reduced eGFR, Sex-specific, Visceral adipose tissue
Background

Chronic kidney disease (CKD) was a disease with heterogeneous etiology that caused 15.8 deaths per 100,000 people worldwide in 2013 and was estimated to attack 119.5 million Chinese people in the year of 2012 [1, 2]. Besides, CKD has been identified to be related with multiple cardiovascular risk factors like hypertension and diabetes mellitus (DM), revealing its close association with cardiovascular health [3, 4]. Therefore, CKD has brought great burden to the health-care work and economy [5, 6]. Knowing the poor outcomes and high cost that caused by CKD as a worldwide public health problem, it is a good choice to focus on the early detection of reduced estimated glomerular filtration rate (eGFR) for avoiding the progression of CKD. Accordingly, early detection of reduced eGFR is critically needed for timely CKD prevention and overall improvement in prognosis.

There is an wealthy evidence that dyslipidemia and obesity are strongly related to the deterioration of renal function, even in the early stage [7, 8]. Dyslipidemia in CKD often exhibits a pattern of increased triglyceride (TG) levels and decreased high density lipoprotein cholesterol (HDL-C) levels [7]. Findings revealed that increased TG level was significantly correlated with CKD [9–11]. Furthermore, as a combination of 2 characteristics of dyslipidemia in CKD, TG to HDL-C ratio (TG / HDL-C) has also been identified to strongly associated with decline of eGFR in participants without CKD and rapid decrement of eGFR in participants with CKD [12–14]. Obesity is another condition that strongly correlated with decreased eGFR or CKD [8, 15]. As the most widely used index of obesity, body mass index (BMI) was revealed to widely correlated with reduced eGFR, CKD and end stage renal disease (ESRD) [16, 17]. However, BMI did not take abdominal obesity into consideration when reflecting obesity status. Therefore, some indexes such as waist circumference (WC) and waist-to-height ratio (WHtR) were designed to be measurements of central obesity [18]. And they have already showed strong associations with CKD [19–22]. Nevertheless, comparisons between BMI, WC and WHtR did not provide sufficient evidence for anyone of them to be a premier marker of CKD with great sensitivity or specificity [19–22]. Moreover, indexes of abdominal obesity were insufficient to detecting visceral adipose tissue (VAT), which was elucidated to possess a more adverse effect on CKD development than subcutaneous adipose tissue (SAT) [23, 24]. However, when cooperating with aforementioned indexes of dyslipidemia, their strength to discriminating VAT got reinforcement [24]. Taken together, combination of dyslipidemia and abdominal obesity could improve the identification of VAT and therefore refine the detecting of reduced eGFR.

Recently, a novel marker named “cardiometabolic index (CMI)” has been put forward by Ichiro Wakabayashi [25]. CMI can be considered as an ideal marker to recognize VAT because of its integration of dyslipidemia and abdominal obesity. This emerging marker has been shown in several studies to be a useful screening tool for various populations, identifying those with a deteriorated metabolic profile and higher risk for cardiovascular disease, such as left ventricular geometry abnormalities, hyperuricemia, diabetes, hypertension, and ischemic stroke [25–29]. It is unclear, however, if CMI can be an identifier of reduced eGFR, independent of cardiovascular risk factors and hypertension. Accordingly, the present study was designed to test whether or not higher CMI increase the risk of reduced eGFR in the general Chinese population.

Methods

Study population

This study was part of a large cross-sectional population-based epidemiological investigation that described the prevalence, incidence, and natural history of cardiovascular disease, such as left ventricular geometry abnormalities, hyperuricemia, diabetes, hypertension, and abdominal obesity. This emerging marker has been put forward by Ichiro Wakabayashi [25]. CMI can be considered as an ideal marker to recognize VAT because of its integration of dyslipidemia and abdominal obesity. This emerging marker has been shown in several studies to be a useful screening tool for various populations, identifying those with a deteriorated metabolic profile and higher risk for cardiovascular disease, such as left ventricular geometry abnormalities, hyperuricemia, diabetes, hypertension, and ischemic stroke [25–29]. It is unclear, however, if CMI can be an identifier of reduced eGFR, independent of cardiovascular risk factors and hypertension. Accordingly, the present study was designed to test whether or not higher CMI increase the risk of reduced eGFR in the general Chinese population.

Data collection and measurements

Detailed process about data collection and measurements was described by previous publications from our research team that involved in the same survey as this study [26, 30, 31]. Cardiologists and nurses completed a training and passed a test before they were allowed to conduct the questionnaire which collected information about demographic data, health-related behavior, anthropometric parameters, dietary condition, current
Definitions

BMI was calculated as mean weight divided by mean height squared (kg/m²). WHtR was acquired as WC divided by mean height. CMI was obtained by the following equation [25]: CMI = TG/HDL-C × WHtR. Lipid accumulation product (LAP) was calculated according to the sex-specific formula [33]: LAP = TG (mmol/L) × [WC (cm)-58] for females and LAP = TG (mmol/L) × [WC (cm)-65] for males. And visceral adiposity index (VAI) was determined by using the following formula [34]: Males: VAI = [WC / 39.68 + (1.89 × BMI)] × (TG / 1.03) × (1.31 / HDL); Females: VAI = [WC / 36.58 + (1.89 × BMI)] × (TG / 0.81) × (1.52/HDL).

eGFR was calculated according to CKD-EPI equation [35]. Reduced eGFR was defined as eGFR < 60 ml/min per 1.73m² [36]. Diagnostic criteria of hypertension were mean systolic blood pressure (SBP) equal to or greater than 140 mmHg and/or diastolic blood pressure (DBP) at least 90 mmHg and/or participants who were on antihypertensive medications or self-reported previous diagnosed hypertension [37]. Diagnosis of diabetes based on the American Diabetes Association criteria: fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or self-reported previous diagnosis history or receiving plasma glucose lowering therapy [38].

Statistical analyses

Analyses were performed in a sex-specific manner. Continuous variables were expressed as mean values ± standard deviation (SD) or as median (interquartile range) if appropriate. Categorical variables were depicted as frequencies (percentages). Continuous variables were compared between groups with Student’s t test or Mann-Whitney test according to their distribution, in the meantime, categorical variables were also compared between groups by using χ² test [39]. As for the comparison of ordinal categorical variables (education level, family annual income, physical activity), rank-sum test was performed in order to get full utilization of the ordinal information. Before inferential analyses, CMI values were log transformed due to highly skewed distributions. The chi-square linear-by-linear association test was used to reveal linear trends across the quartiles of CMI for percentages of prevalence of reduced eGFR. Multivariate linear regression analysis was conducted to evaluate the independent effect of CMI on eGFR value. And logarithmic likelihood ratio test was employed to compare the one-line linear regression model with a two-piecewise linear model. Furthermore, multivariate logistic regression analysis was performed to explore the isolated association of CMI as a continuous variable and as quartiles with the prevalence of reduced eGFR. Sex-specific odds ratios (ORs) for every SD change of CMI to identify the risk of reduced eGFR were acquired.
the results were displayed as ORs and 95% confidence intervals (95% CI). Lastly, receiver-operating characteristic (ROC) curve was employed to investigate the optimal cut-off value of CMI to detect the presence of reduced eGFR. Area under the curve (AUC) was used to compare the discriminating ability of CMI and other indexes. All of the statistical analyses involved were performed by SPSS 25.0 software (IBM corp), statistical software packages R (http://www.R-project.org, The R Foundation) and EmpowerStats (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA), Prism 7.0 software (Graphpad software, Inc) and MedCalc version 18.5 (MedCalc software, Belgium), a two-tailed \( P \) value less than 0.05 indicated statistical significant.

**Results**

After excluding ineligible participants, we finally took 11,578 subjects into analyses, the results were shown in Table 1. Of these subjects, 46.3% were males. The mean age of total population was 53.8 years while people with eGFR decrement were elder than their counterparts in both genders. The prevalence of reduced eGFR was 1.7% in males while females exhibited a higher rate of 2.5%. As for the demographic information, education level, family annual income, diet score and physical activity exhibited significant lower levels in patients with reduced eGFR. Contradictorily, female patients were more likely to smoke at present but male patients tended not to be a current smoker. Only males showed significant difference on alcoholic status between groups, but the results revealed that normal eGFR subjects had greater possibility to be a current drinker. With regard to laboratory test results, FPG, serum uric acid, TG and TG/HDL-C confirmed a remarkable augmentation among eGFR decrement patients, together with a dramatically decline of HDL-C in patients. SBP, height, WC, WHtR showed great increment when comparing CKD patients with their counterparts regardless of sex. But DBP only exhibited higher level in male patients while less weight was specific to female patients. Prevalence of hypertension and diabetes were noticeable higher among subjects with reduced eGFR for both genders, and the usages of anti-hypertensive, anti-diabetic and lipid-lowering drug were more popular in reduced eGFR group. Concordantly, the prevalence of cardiovascular and kidney diseases history showed dramatic augmentation in eGFR reduction patients of both genders. Within our expectation, patients with reduced eGFR of both genders experienced pronounced increment of CMI, VAI as well as LAP.

Quartile analyses revealed gradient correlation between CMI and prevalence of reduced eGFR, as displayed in Fig. 1. When comparing the top quartile with the bottom one, males exhibited a 6.0-fold change for the probability of eGFR reduction while females showed a higher fold change of 8.2. Both genders confirmed linear trends of prevalent eGFR reduction across quartiles of CMI (all \( P \) for trend<0.001).

Results of linear regression analyses identified robust negative association between CMI with eGFR. As presented in Table 2, logarithmic likelihood ratio test identified the association between CMI and eGFR was non-linear in both genders after adjustment of age, race, education level, family annual income, diet score, physical activity, current smoking, alcohol intake, hypertension, diabetes, antihypertensive drug, anti-diabetic drug, lipid-lowering drug, history of cardiovascular and kidney diseases. In the full model of males, the two-piecewise linear model revealed a rapid decrease of eGFR value along with the early increase of normalized CMI, with a \( \beta \) value of \(-3.150\) (\(-3.589, -2.712\)). However, when normalized CMI reached 1.113 (equaled to 1.210 of CMI), the change of eGFR shifted to a mild increase, with a \( \beta \) value of 1.906 (0.675, 3.138). Similarly, in the complete model of females, the eGFR also suffered a loss of 2.411 ml/min per 1.73m\(^2\) for each SD increase of CMI before normalized CMI arrived to 1.472 (equaled to 1.520 of CMI). But after that, the eGFR began to have an increment of 2.268 ml/min per 1.73m\(^2\) along with every single unit increase of normalized CMI.

Logistic regression analyses confirmed the intensive relationship between CMI with reduced eGFR, the results were arranged in Table 3. In males, per 1 SD increase of CMI still caused 52% of additional risk for eGFR reduction after adjusting all included cofounders. When divided into quartiles, highest quartile of CMI displayed 4.2 times risk for developing eGFR decrement compared with lowest category in the full model, and there was a significant linear trend for the risk of eGFR reduction across the quartiles of CMI (\( P \) for trend<0.001).

Similar results were observed in female participants, risk of eGFR reduction got an elevation of 34.7% for every single SD increment of CMI. Furthermore, the ORs for top quartile compared with bottom group was 3.442 (1.685–7.031), and the linear trend across quartiles also existed (\( P \) for trend<0.001). We further conducted a test for the interaction between genders and CMI, and the results displayed to be insignificant, identifying the robust association between CMI and reduced eGFR across genders.

ROC analyses showed a significant AUC value of CMI for discriminating eGFR reduction, the results were summarized in Table 4. In males, our findings displayed that CMI possessed the greatest AUC (AUC: 0.633, 95% CI: 0.620–0.646) among various indexes, statistically significantly higher than that of LAP (AUC 0.633 vs. 0.606, \( P = 0.036 \)) and BMI (AUC 0.633 vs. 0.544, \( P = 0.004 \)), and there was also a trend for CMI to be superior than VAI (0.627, 0.614–0.640). Meanwhile, CMI showed a
| Variables                        | Males (n = 5360) | Females (n = 6218) | P value* | Males (n = 5360) | Females (n = 6218) | P value* |
|---------------------------------|------------------|--------------------|----------|------------------|--------------------|----------|
| **Age (years)**                 | 68.78 ± 10.41    | 54.11 ± 10.64      | < .001   | 68.69 ± 8.87     | 52.99 ± 10.08      | < .001   |
| **Race (Han) (%)**              | 87 (96.7)        | 4987 (94.6)        | 0.394    | 152 (98.1)       | 5747 (94.8)        | 0.068    |
| **Education level (%)**         |                  |                    | < .001   |                  |                    | < .001   |
| Primary school or below         | 57 (63.3)        | 2177 (41.3)        |          | 135 (87.1)       | 3398 (56.0)        |          |
| Middle school                   | 26 (28.9)        | 2487 (47.2)        |          | 18 (11.6)        | 2187 (36.1)        |          |
| High school or above            | 7 (7.8)          | 606 (11.5)         |          | 2 (1.3)          | 478 (7.9)          |          |
| **Income level (CNY) (%)**      |                  |                    | < .001   |                  |                    | < .001   |
| ≤ 5000                          | 28 (31.1)        | 693 (13.1)         |          | 41 (26.5)        | 680 (11.2)         |          |
| 5000 – 20,000                   | 45 (50.0)        | 2827 (53.6)        |          | 77 (49.7)        | 3361 (55.4)        |          |
| > 20,000                        | 17 (18.9)        | 1750 (33.2)        |          | 37 (23.9)        | 2022 (33.3)        |          |
| **Diabetes (%)**                |                  |                    |          |                  |                    |          |
| Current smoking (%)             | 28 (31.1)        | 3030 (57.5)        | < .001   | 43 (27.7)        | 987 (16.3)         | < .001   |
| Current alcohol intake (%)      | 14 (15.6)        | 2421 (45.9)        | < .001   | 3 (1.9)          | 180 (3)           | 0.452    |
| FPG (mmol/L)                    | 5.74 (5.35 – 6.67)| 5.60 (5.22 – 6.09) | 0.010    | 5.78 (5.30 – 7.05)| 5.49 (5.12 – 5.99)| < .001   |
| Serum uric acid (μmol/L)        | 447.52 ± 122.56  | 331.80 ± 81.34     | < .001   | 363.21 ± 94.01   | 253.06 ± 64.66     | < .001   |
| TG (mmol/L)                     | 1.41 (1.10 – 2.07)| 1.22 (0.86 – 1.88) | 0.006    | 1.86 (1.30 – 2.55)| 1.24 (0.89 – 1.88) | < .001   |
| HDL-C (mmol/L)                  | 1.21 ± 0.27      | 1.41 ± 0.42        |          | 1.35 ± 0.41      | 1.41 ± 0.34        | 0.018    |
| TG/HDL-C                        | 1.19 (0.80 – 2.11)| 0.91 (0.57 – 1.57) | < .001   | 1.42 (0.92 – 2.24)| 0.92 (0.59 – 1.51) | < .001   |
| SBP (mmHg)                      | 161.58 ± 26.32   | 143.36 ± 22.43     | < .001   | 154.16 ± 26.14   | 139.79 ± 23.87     | < .001   |
| DBP (mmHg)                      | 89.01 ± 16.20    | 83.69 ± 11.71      | 0.003    | 82.57 ± 14.77    | 80.52 ± 11.41      | 0.088    |
| Height (cm)                     | 164.08 ± 5.56    | 166.46 ± 6.35      | < .001   | 152.91 ± 5.91    | 155.69 ± 6.06      | < .001   |
| Weight (kg)                     | 68.52 ± 12.06    | 68.61 ± 11.10      | 0.040    | 58.08 ± 10.64    | 60.33 ± 10.11      | 0.006    |
| BMI (kg/m²)                     | 25.36 ± 3.65     | 24.72 ± 3.54       | 0.091    | 24.77 ± 3.95     | 24.86 ± 3.76       | 0.778    |
| WC (cm)                         | 87.05 ± 10.36    | 83.74 ± 9.75       | 0.003    | 84.07 ± 10.37    | 81.20 ± 9.71       | < .001   |
| WHtR                            | 0.53 ± 0.06      | 0.50 ± 0.06        | < .001   | 0.55 ± 0.07      | 0.52 ± 0.06        | < .001   |
| hypertension (%)                | 74 (82.2)        | 2818 (53.5)        | < .001   | 120 (77.4)       | 2907 (47.9)        | < .001   |
| diabetes (%)                    | 22 (24.4)        | 508 (96.5)         | < .001   | 41 (26.5)        | 629 (10.4)         | < .001   |
| Anti-hypertensive drug (%)      | 50 (55.6)        | 641 (12.2)         | < .001   | 73 (47.1)        | 989 (16.3)         | < .001   |
| Anti-diabetic drug (%)          | 13 (14.4)        | 148 (2.5)          | < .001   | 20 (12.9)        | 278 (4.6)          | < .001   |
| Lipid-lowering drug (%)         | 7 (7.8)          | 159 (3.0)          | 0.021    | 12 (7.7)         | 202 (3.3)          | 0.003    |
| history of CVD (%)              | 46 (51.1)        | 781 (14.8)         | < .001   | 62 (40.0)        | 1092 (18.0)        | < .001   |
| history of kidney disease (%)   | 5 (5.6)          | 60 (1.1)           | < .001   | 11 (7.1)         | 77 (1.3)           | < .001   |
| eGFR (ml/min per 1.73m²)        | 54.81 (46.46 – 57.67)| 95.44 (87.00 – 103.44)| < .001  | 52.90 (46.89 – 57.47)| 93.23 (82.89 – 103.29)| < .001  |
| LAP (cm/mmol/L)                 | 31.88 (18.63 – 51.35)| 21.79 (10.62 – 43.35)| 0.001    | 44.94 (26.00 – 77.56)| 27.84 (16.00 – 50.25)| < .001  |
| VAI                             | 1.51 (1.00 – 2.60)| 1.12 (0.68 – 1.98) | < .001   | 2.68 (1.78 – 4.17)| 1.67 (1.06 – 2.78) | < .001   |
| CMI                             | 0.62 (0.41 – 1.10)| 0.45 (0.27 – 0.82) | < .001   | 0.81 (0.49 – 1.26)| 0.47 (0.29 – 0.81) | < .001   |

Data are expressed as mean ± standard deviation (SD) or median (interquartile range) and numbers (percentage) as appropriate. Income level: family annual income; CNY Chinese currency [1CNY = 0.15 USD], SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, CVD cardiovascular disease, includes coronary heart disease, arrhythmia, heart failure, and stroke; Kidney disease: includes nephritis, kidney dysfunction, renal stones, renal tumor, and autoimmune kidney disease. Body mass index; WC waist circumference, WHtR waist-to-height ratio; TG triglyceride; HDL-C high density lipoprotein cholesterol, TG/HDL-C triglyceride to high density lipoprotein cholesterol ratio, eGFR estimated glomerular filtration rate, LAP lipid accumulation product, VAI visceral adiposity index, CMI cardiometabolic index

*Comparisons of category variables between groups were tested by chi-square test or rank-sum test (ordinal category variables) and comparisons for continuous variables between groups were tested by Student’s t or Mann-Whitney test.
sensitivity of 88.9% and a specificity of 37.1%. In females, CMI had an AUC (AUC: 0.684, 95% CI: 0.672–0.695) which was comparable to that of VAI (AUC: 0.688, 95% CI: 0.676–0.699, P value for difference = 0.148) and statistically significantly greater than that of LAP (AUC 0.684 vs 0.660, P = 0.047), WC (AUC 0.684 vs 0.588, P < 0.001) and BMI (AUC 0.684 vs 0.500, P < 0.001). Furthermore, CMI exhibited the greatest sensitivity (89.0%) in this gender. However, the specificity was still low and was given to 39.8%.

Discussion

Our study showed that in this large, community-based cohort of middle-aged Chinese individuals, CMI, a novel measure of VAT, was independently and robustly associated with the presence of reduced eGFR in both genders. CMI could reflect not only VAT but also pathologic process that resulted in impaired kidney function, thus provided a clinical clue for related basic researches. As our results revealed the potential of CMI as a screening marker of reduced eGFR, further understanding of the underlying pathophysiology should improve strategies to prevent and potentially reverse detrimental kidney failure and cardiovascular outcomes, especially in people with poor socioeconomic conditions.

Dyslipidemia is a condition that always appears in the development of CKD, even in the early stage of eGFR reduction, and the major components of dyslipidemia in CKD has been revealed to be increased TG level and decreased HDL-C level [7]. Indexes that represent this specific pattern has been identified to have a strong correlation with CKD. For instance, Hou et al. revealed that TG level was closely associated with mildly decreased eGFR even among middle aged or elderly Chinese population. It was worthy to note that this relationship existed when TG level was still in the normal range. This finding gave us an implication that increased TG level could appear in the early process of decreased eGFR [9]. Lee et al. identified hypertriglyceridemia as an independent risk factor of progressed CKD, confirmed the association persistent in middle and late stage of CKD [11]. Furthermore, Tozawa et al. and Shimizu et al. provided compelling evidences that TG had an independent effect to increase the risk of eGFR decrement from longitudinal studies, Tozawa et al. also identified HDL-C positively related to eGFR value and revealed TG had an impact on the development of proteinuria [10, 40]. Apart from above investigations, researches also identified the utility of TG/HDL-C in identifying eGFR reduction as it incorporated both TG and HDL-C level. Ho et al. demonstrated the correlation between TG/HDL-C with CKD, and Wen et al. even showed the advantage of TG/HDL-C when compared with TG alone with respect to the development of CKD, confirmed our aforementioned hypothesis [13, 14]. However, there was one point that worth to be mentioned, although TG/HDL-C had a robust association with CKD, it was not an ideal marker of eGFR reduction due to its low sensitivity and specificity [13].

As another condition that always accompany with CKD, obesity is related to multiple risk factors of CKD, such as hypertension and diabetes [41, 42]. Its direct association with CKD has been evaluated through indexes. As the most widely used index of obesity, BMI has already been elucidated to have a connection with new-onset CKD, CKD progression and end stage renal failure [16, 17, 43]. However, since BMI do not consider adipose tissue distribution, there is no doubt that BMI is unsuitable for reflecting the relationship between obesity phenotype with CKD. Therefore, indexes of abdominal
A regression model was applied to explore the non-linear association between CMI and eGFR. Females alone but could recognize VAT correctly when working. VAT contributed more to CKD than SAT [23].

Indexes that integrate both abdominal obesity and dyslipidemia have been proposed. Determined by WC and TG levels, LAP was put forward for recognizing cardiovascular risk [33], and it has also been identified to possess a stronger association with CKD than BMI, WC and WHtR [45]. Later, a concept named VAI was posited as an indicator of cardiometabolic risk with an additional consideration of HDL-C and BMI when compared with LAP [34]. In recent studies, VAI showed strong association with

Table 2 Evaluation of the impact of CMI on eGFR value with the use of piecewise linear regression

|          | Unadjusted | MV adjusted |
|----------|------------|-------------|
| Males    |            |             |
| Linear model | β Value (95% CI) | P value | β Value (95% CI) | P value |
|          |            |           | -1.850 (-2.259, -1.440) | < 0.001 | -2.214 (-2.561, -1.866) | < 0.001 |
| Non-linear model | Breakpoint (K) | 1.024 | 1.113 |
|          | β 1 (<K) (95% CI) | P value | β 2 (>K) (95% CI) | P value |
|          | -3.324 (-3.863, -2.786) | < 0.001 | 3.777 (2.371, 5.182) | < 0.001 |
|          | Logarithmic likelihood ratio test | P value | < 0.001 | 1.906 (0.675, 3.138) | 0.002 |
|          |            |           | < 0.001 | 2.478 (0.636, 4.320) | 0.008 |
|          |            |           | 2.268 (0.547, 3.988) | 0.010 |
| Females  |            |             |
| Linear model | β Value (95% CI) | P value | β Value (95% CI) | P value |
|          |            |           | -4.046 (-4.438, -3.654) | < 0.001 | -1.914 (-2.262, -1.566) | < 0.001 |
| Non-linear model | Breakpoint (K) | 1.34 | 1.472 |
|          | β 1 (<K) (95% CI) | P value | β 2 (>K) (95% CI) | P value |
|          | -5.001 (-5.472, -4.530) | < 0.001 | 2.478 (0.636, 4.320) | 0.008 |
|          | Logarithmic likelihood ratio test | P value | < 0.001 | 2.268 (0.547, 3.988) | 0.010 |

Abbreviations: CMI cardiometabolic index, OR odds ratio, 95% CI 95% confidence interval. Linear model: model that presumes the association between CMI and eGFR is linear. Non-linear model: model that presumes the association between CMI and eGFR is non-linear and has breakpoint. Unadjusted: no adjustment; MV adjusted: multivariable adjusted model, includes age, race, education level, family annual income, physical activity, current smoking, current alcohol intake, hypertension, diabetes, antihypertensive drug, antidiabetic drug, lipid-lowering drug, history of cardiovascular disease and kidney disease. *Two-step linear regression model was applied to explore the non-linear association between CMI and eGFR.

Table 3 Sex-specific logistic regression models for reduced eGFR with CMI

| Males | Unadjusted OR (95% CI) | P value | MV adjusted OR (95% CI) | P value | Females | Unadjusted OR (95% CI) | P value | MV adjusted OR (95% CI) | P value | P for interaction |
|-------|------------------------|---------|------------------------|---------|---------|------------------------|---------|------------------------|---------|------------------|
| CMI (Per 1 SD increase) | 1.457 (1.211, 1.777) | < 0.001 | 1.516 (1.182, 1.943) | 0.001 | 1.760 (1.519, 2.040) | < 0.001 | 1.347 (1.122, 1.618) | 0.001 | 0.172 |
| Quartiles of CMI | | | | | | | | | |
| Quartile 1 | 1.000 | 1.000 | 1.000 | 1.000 | | | | | |
| Quartile 2 | 3.711 (1.500, 9.182) | 0.005 | 2.717 (1.061, 6.957) | 0.037 | 2.835 (1.372, 5.856) | 0.005 | 2.285 (1.069, 4.888) | 0.033 |
| Quartile 3 | 5.092 (2.112, 12.273) | < 0.001 | 3.867 (1.551, 9.640) | 0.004 | 4.187 (2.090, 8.387) | < 0.001 | 2.509 (1.204, 5.225) | 0.014 |
| Quartile 4 | 5.439 (2.267, 13.052) | < 0.001 | 4.227 (1.681, 10.627) | 0.002 | 7.939 (4.091, 15.408) | < 0.001 | 3.442 (1.685, 7.031) | < 0.001 |
| P value for trend | < 0.001 | < 0.001 | < 0.001 | < 0.001 |

MV indicates multivariable, OR odds ratio, CI confidence interval, CMI cardiometabolic index. Cut points for CMI: Men: ≤ 0.27, > 0.27 and ≤ 0.46, > 0.46 and ≤ 0.83, > 0.83; Women: ≤ 0.30, > 0.30 and ≤ 0.48, > 0.48 and ≤ 0.82, > 0.82. MV model adjusted for age, race, education level, family annual income, diet score, physical activity, current smoking, current alcohol intake, hypertension, diabetes, antihypertensive drug, antidiabetic drug, lipid-lowering drug, history of cardiovascular disease (coronary heart disease, arrhythmia, heart failure, and stroke) and kidney disease (nephritis, kidney dysfunction, renal stones, renal tumor, and autoimmune kidney disease).

Indexes that integrate both abdominal obesity and dyslipidemia have been proposed. Determined by WC and TG levels, LAP was put forward for recognizing cardiovascular risk [33], and it has also been identified to possess a stronger association with CKD than BMI, WC and WHtR [45]. Later, a concept named VAI was posited as an indicator of cardiometabolic risk with an additional consideration of HDL-C and BMI when compared with LAP [34]. In recent studies, VAI showed strong association with together with TG [24, 44]. Taking all above messages together, we can speculate that indexes contain information about dyslipidemia and abdominal obesity should do better in the identification of VAI and be able to refine the recognition of eGFR reduction.
CKD and greater potential as a marker of eGFR reduction than LAP as well as traditional anthropometric indexes [45, 46]. However, these two novel indexes still have limitations. Both LAP and VAI have sex-specific equations, and VAI has a sophisticated algorithm, these will increase the complexity of calculation. As for LAP, information about HDL-C is not utilized, which is an important aspect of dyslipidemia in CKD. Moreover, height info is also wasted by LAP, but people with different height should have different WC standard. Last but not least, although VAI possessed a greater discriminative power than LAP and other indexes, it still failed to reach satisfying sensitivity and specificity values, thus its value for becoming a marker of eGFR reduction is limited [46].

CMI is a young index which was posited by Ichiro Wakabayashi in 2015 [25]. Different from LAP and VAI, it reflects both characteristics of dyslipidemia in CKD and accurate central obesity status through a simple, generalized eq. CMI has also been identified to correlate with multiple cardiovascular risk factors, implicated to have a great potential in screening related diseases [25–29]. Since many of these diseases has been identified to be risk factors of CKD [16, 47–50], we hypothesize that CMI correlates with reduced eGFR and is capable of being a premier indicator of eGFR decrement. In our present study, regression analyses revealed the intensive and direct associations of CMI with eGFR value and eGFR reduction in both genders, confirming above hypothesis. Moreover, we observed a breakpoint in the association between CMI and eGFR value, which meant the change of eGFR shifted from decrease to increase after CMI reached certain value. And this phenomenon was robust and persistent across genders. Although the exact mechanism underlying this paradoxical phenomenon is still unclear, some previous findings can also give us a clue for possible explanations. While obesity was commonly considered to associate with the decline of eGFR [8, 15], studies also found a protective effect of obesity on CKD patients [51, 52], and this protective effect could be explained by the evidence that excessive adipose tissue might temper the deleterious effects of inflammatory factors by sequestering them [53, 54]. Consistent with this theory, the breakpoint was located at high levels of CMI (> 75 percentile) in each gender, which meant that the protective effect became more predominant than the destructive effect only when fatty tissue accumulated to a sufficient volume. Another possible explanation was the residual confounders. Although we had adjusted several factors that related to CMI and eGFR, there were still some confounders that we did not take into our regression equations. Therefore, some uncovered confounding factors could influence our results and caused this paradox. In order to validate the paradox founded in the present study, studies with prospective design and consideration of more modifiers are needed in the future.

Further, we confirmed the association between CMI and reduced eGFR was positive and strong. We found that the risk of reduced eGFR was proportionally increased across the quartiles of CMI, which was different from the breakpoint phenomenon in the association between CMI and eGFR value. Given that the breakpoint of CMI located behind the 75 percentile in both genders, we could easily figure out that the limited increase of eGFR in CMI levels above the breakpoint has minimal effect on the whole inverse trend of CMI with reduced kidney function (eGFR< 60 ml/min per 1.73m²). We also

### Table 4 AUC for indexes to discriminate eGFR reduction in females and males

| Variables | AUC (95%CI) | P value | Cut-off according to Youden’s index | Sensitivity (%) | Specificity (%) |
|-----------|-------------|---------|-------------------------------------|----------------|-----------------|
| **Males** |             |         |                                     |                |                 |
| CMI       | 0.633 (0.620–0.646) | < 0.001 | > 0.35 | 88.9% | 37.1% |
| VAI       | 0.627 (0.614–0.640)  | < 0.001 | > 0.83 | 90.0% | 34.7% |
| LAP       | 0.606 (0.593–0.619)  | < 0.001 | > 18.33 | 77.8% | 43.6% |
| WC        | 0.589 (0.576–0.602)  | 0.001   | > 79.1 | 83.3% | 35.0% |
| BMI       | 0.544 (0.531–0.558)  | 0.135   | > 22.02 | 88.9% | 22.8% |
| **Females** |           |         |                                     |                |                 |
| CMI       | 0.684 (0.672–0.695) | < 0.001 | > 0.39 | 89.0% | 39.8% |
| VAI       | 0.688 (0.676–0.699)  | < 0.001 | > 1.69 | 80.0% | 50.4% |
| LAP       | 0.660 (0.648–0.672)  | < 0.001 | > 36.12 | 65.2% | 61.8% |
| WC        | 0.588 (0.576–0.600)  | < 0.001 | > 84.20 | 52.9% | 64.0% |
| BMI       | 0.500 (0.488–0.513)  | 0.999   | ≤ 27.81 | 76.1% | 20.1% |

Abbreviations: AUC area under the ROC curve, 95% CI 95% confidence interval, CMI cardiometabolic index, VAI visceral adiposity index, LAP lipid accumulation product, WC waist circumference, BMI body mass index

*a* indicates a significant larger as compared to LAP;

*b* indicates a significant larger as compared to WC;

*c* indicates a significant larger as compared to BMI.
noticed that males had a slightly higher risk of developing reduced eGFR when compared with their female counterparts. But the interaction test revealed that this disadvantage was statistically insignificant. However, although we could not conclude that males were under greater risk of reduced eGFR, we still elucidated that CMI had a robust association with eGFR reduction in both genders, identifying the utility and stability of CMI for the risk stratification of reduced eGFR.

Findings from ROC analyses provided compelling evidence for CMI to be a screening marker of CKD. In males, CMI possessed greatest AUC value, although it did not have a significant larger discriminating ability than VAI, the simple and generalized equation for both sexes would be a vantage. With a sensitivity of 88.9%, CMI demonstrated its capability to function well in the screening test, since more suspicious patients should be positive in this kind of examination. It was worthy to note that neither of CMI, VAI and LAP had a significant greater AUC than WC, which was beyond our expectation, this could be explained by the lacking of sample size since the absolute number and prevalence of reduced eGFR were much lower in males than in females. Further studies are needed to validate this intriguing finding. In females, CMI did an even better job as it performed better than other indexes significantly except VAI. Although exhibited a negligible disadvantage in discriminating eGFR reduction, CMI showed a much higher sensitivity than VAI, thus the applicative value for CMI was still superior than VAI among females. In conclusion, with great discriminative ability and high sensitivity value, CMI showed its potential for becoming an economic screening marker to filter out people with reduced eGFR.

Mounting evidence has emerged to reveal the mechanism under the association between CMI with CKD. First, mechanism of dyslipidemia in CKD has already been elucidated. Hypertriglyceridemia is a multifactorial phenomenon, and is partially due to diminished catabolism. This reduction is an outcome of depressed lipoprotein lipase (LPL) activity, which is responsible for the hydrolysis of TG [55]. And the decreased LPL activity has been identified to be caused by secondary hyperparathyroidism induced insulin resistance (IR) and excess of lipase inhibitors like apolipoprotein (Apo) C-III in the progression of CKD [56, 57]. For another aspect, hepatic Apo A-I gene expression and hepatic lecithin cholesterol acyl transferase (LCAT) mRNA expression are downregulated during the course of CKD, and then this change attributes to a lower plasma Apo A-I level and decreased LCAT activity [58, 59]. Since Apo A-I is an essential functional component of HDL-C [60], the concentration of HDL-C in blood is consequently decreased. Similarly, the normal function of HDL-C is also impaired because of inadequate LCAT activity, which is important in the process of transporting cholesterol to HDL in peripheral tissues [60]. Second, basic research has also revealed the intrinsic mechanism between obesity with CKD. Adipocytes produce a series of factors, such as angiotensinogen, precursor of angiotensin II and leptin, which may trigger glomerular hypertension through local renin-angiotensin-aldosterone system (RAAS) or sympathetic system, then leading to the decrease of eGFR [8]. Furthermore, inflammation involves in the association between obesity with CKD as well, macrophages are found to accumulate in the kidney of obese animals in the effect of angiotensin [61]. Some inflammatory cytokines such as interleukin-6 (IL-6) and Tumor necrosis factor-α (TNF-α) have also been implicated in obesity-related CKD [62]. Therefore, obesity could promote the progression of renal disease through several, partially overlapping mechanisms. Sum up above two points, as composites of CMI, dyslipidemia and obesity have experiment confirmed relationship with CKD. Thus, the association between CMI with reduced eGFR observed in our study has a concrete foundation from basic researches.

There are still some limitations in our study that needed to be mentioned. First, due to the cross-sectional design, our work can only provide evidence about the strong association between CMI and reduced eGFR, but information about the causality of this relationship need further prospective studies to confirm. Second, it has an inherent limitation of not being a randomized study. Although multivariable adjustments were performed for potential confounding factors, a possible effect of unmeasured variables such as C-reactive protein cannot be excluded. Third, our study participants were recruited from rural area of northeast of China, whether the results can be applied to populations of different areas or races require more studies to investigate. Finally, our diagnosis based on a single biochemistry test, the creatinine value could be influenced by uncertain factors, thus the accuracy of eGFR could be mildly disturbed.

**Conclusions**

In summary, our work was the first study to reveal the relationship between CMI and reduced eGFR which was independent of prevalent CVD, medication used, and conventional cardiovascular risk factors. Thus, these data provide strong evidence of a unique, independent and economic role of CMI in a high burden of kidney disease. These findings have important implications for guiding primordial prevention and understanding the mechanisms underlying VAT-mediated renal injury.

**Abbreviations**

AUC: Area under the curve; BMI: Body mass index; CI: Confidence interval; CMI: Cardiometabolic index; CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate; HDL-C: High-density lipoprotein cholesterol; IL-6: Interleukin-6; LCAT: Lecithin cholesterol acyl transferase; RAAS: Renin-angiotensin-aldosterone system; ROC: Receiver operating characteristic; WC: Waist circumference; VAI: Visceral adiposity index; VAT: Visceral adipose tissue; CVD: Cardiovascular disease.
Competing interests

Consent for publication

Acknowledgements

We would like to express our gratitude to all those who exert their efforts in achieving this study.

Authors' contributions

In this study, HYW and WRS did the study design, statistical analyses and interpretation of data. The corresponding author was YXS. All authors achieved this study.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Ethics Committee of China Medical University (Shenyang, China) approved the study protocol. All participants and all procedures were performed in accordance with the ethical standards. The Ethics Committee of China Medical University (Shenyang, China) approved the study protocol.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Cardiology, The First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang 110001, China.
2Department of Cardiovascular Medicine, Beijing Moslem Hospital, Beijing 100054, China.
3Department of Computer Medical and Bioinformatics, University of Michigan, 100 Washtenaw Avenue, Ann Arbor, MI 48109, USA.
4West China School of Medicine, Schuan University, #37 Guoxue Alley, Chengdu 610041, China.

Received: 23 July 2018 Accepted: 12 October 2018

Published online: 25 October 2018

References

1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117–71.
2. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379:815–22.
3. Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis. 2015;22:88–95.
4. Levey A, Astor B, Stevens L, Corej J. Chronic kidney disease, diabetes, and hypertension: what’s in a name? Kidney Int. 2010;78:19–22.
5. Nugent R, Fatima S, Feigl A, Chyung D. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract. 2011;118:c269–77.
6. Luyckx V, Tonelli M, Stanifer J. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96:14–22.
7. Hager M, Narla A, Tannock L. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18:29–40.
8. Mallamaci F, Trigepi G. Obesity and CKD progression: hard facts on fat CKD patients. Nephrol Dial Transplant. 2013;28:i105–i8.
9. Hou X, Wang C, Zhang X, Zhao X, Wang Y, Li C, et al. Triglyceride levels are closely associated with mild declines in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. PLoS One. 2014;9:e106778.
10. Shimizu M, Furusyo N, Mitsumoto F, Takayama K, Ura K, Hiramine S, et al. Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa population study (KOPS). Atherosclerosis. 2015;238:207–12.
11. Lee P, Chang H, Tung C, Hsu Y, Lee C, Chang H, et al. Hypertriglyceridemia: an independent risk factor of chronic kidney disease in Taiwanese adults. Am J Med Sci. 2009;338:185–9.
12. Tsuney K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66:972–83.
13. Ho C, Chen J, Chen S, Tsai Y, Weng Y, Tsao Y, et al. Relationship between TG/HDL-C ratio and metabolic syndrome risk factors with chronic kidney disease in healthy adult population. Clin Nutr. 2015;34:874–80.
14. Wen J, Chen Y, Huang Y, Lyu Y, Liu X, Zhou H, et al. Association of the TG/HDL-C and non-HDL-C/HDL-C ratios with chronic kidney disease in an adult Chinese population. Kidney Blood Press Res. 2017;42:1141–54.
15. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the hypertension detection and follow-up program. Am J Kidney Dis. 2005;45:587–94.
16. Fox C, Larson M, Leip E, Cullen B, Wilson P, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.
17. Ejeblad E, Fored C, Lindblad P, Fryzek J, McLaughlin J, Nyren O. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.
18. Bacopoulou F, Efthymiou V, Landis G, Rentonins A, Chrousos G. Waist circumference, waist-to-hip ratio and waist-to-height ratio reference percentiles for abdominal obesity among Greek adolescents. BMC Pediatr. 2015;15:50.
19. He Y, Li F, Wang F, Ma X, Zhao X, Zeng Q. The association of chronic kidney disease and waist circumference and waist-to-height ratio in Chinese urban adults. Medicine (Baltimore). 2016;95:e3769.
20. Lin C-H, Chou C-Y, Lin C-C, Huang C-C, Liu C-S, Lai S-W. Waist-to-height ratio is the best index of obesity in association with chronic kidney disease. Nutrition. 2007;23:788–93.
21. Odagiri K, Mizuta I, Yamamoto Y, Watanabe H, Uehara A. Waist to height ratio is an independent risk factor for the incidence of chronic kidney disease. PLoS One. 2014;9:e88873.
22. Dong Y, Wang Z, Chen Z, Wang X, Zhang L, Nie J, et al. Comparison of visceral, body fat indices and anthropometric measures in relation to chronic kidney disease among Chinese adults from a large scale cross-sectional study. BMJ Nephrol. 2018;19:140.
23. Madero M, Katz R, Murphy R, Newman A, Patel K, Ix J, et al. Comparison between different measures of body fat with kidney function decline and incident CKD. Clin J Am Soc Nephrol. 2017;12:893–903.
24. Després J, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28:1039–49.
25. Wakabayashi I, Daimon T. The "cardiometabolic index" as a new marker of cardiovascular disease: a practical tool for screening patients with metabolic syndrome. J Card Metab. 2014;9:268–71.
26. Wang H, Chen Y, Sun G, Ja P, Qian H, Sun Y. Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting
the risk of hypertension in Chinese population. Postgrad Med. 2018;130:325–33.
27. Wang H, Sun Y, Li Z, Guo X, Chen S, Ye N, et al. Gender-specific contribution of cardiometabolic index and lipid accumulation product to left ventricular geometry change in general population of rural China. BMC Cardiovasc Disord. 2018;18:62.
28. Wang H, Chen Y, Guo X, Chang Y, Sun Y. Usefulness of cardiometabolic index for the estimation of ischemic stroke risk among general population in rural China. Postgrad Med. 2017;129:834–41.
29. Dursun M, Biesirgolu H, Otuncemar A, Ozbek E. Association between cardiometabolic index and erectile dysfunction: a new index for predicting cardiovascular disease. Kardisalj J Med Sci. 2016;32:620–3.
30. Li Z, Guo X, Zheng L, Yang H, Sun Y. Gtim status of hypertension in rural China: results from Northeast China rural cardiovascular health study 2013. J Am Soc Hypertens. 2015;9:358–64.
31. Wang H, Li Z, Guo X, Chen Y, Chen S, Tian Y, et al. Contribution of non-traditional lipid profiles to reduced glomerular filtration rate in H-type hypertension population of rural China. Ann Med. 2018;50:249–59.
32. Chen S, Guo X, Dong S, Li Z, Sun Y. Relationship between lifestyle factors and hyperhomocysteinemia in general Chinese population: a cross-sectional study. Postgrad Med. 2017;129:216–23.
33. Kahn H. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26.
34. Amato M, Giordano C, Cilia M, Criscimanna A, Vitaire S, Midiri M, et al. Visceral adiposity index: a reliable indicator of visceral fat fraction associated with cardiometabolic risk. Diabetes Care. 2010;33:920–2.
35. Levey A, Stevens L, Schmid C, Zhang Y, Castro A, Feldman H, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
36. Stevens P, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30.
37. Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo J, et al. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.
38. Zannis V, Chroni A, Kriege M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med. 2006;84:F925–30.
39. Vaziri N, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1926–35.
40. Vaziri N, Deng G, Liang K, Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14:146–2.
41. Vaziri N, Liang K, Parks J. Down-regulation of hepatic lectin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001; 59:2192–6.
42. Mohamed-AlI V, Goodrick S, Bulmer K, Holly J, Yudkin J, Coppel S. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Phys. 1999;277:E971–5.
43. Drechsler C, Wanner C. The obesity paradox and the role of inflammation. J Am Soc Nephrol. 2016;27:1270–2.
44. KORN E. Clearing factor, a heparin-activated lipoprotein lipase. II. Substrate specificity and activation of coconut oil. J Biol Chem. 1955;215:15–26.
45. Dai D, Chang Y, Chen Y, Chen S, Yu S, Guo X, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Phys. 1999;277:E971–5.
46. 27. Wang H, Li Z, Guo X, Chen Y, Chen S, Tian Y, et al. Contribution of non-traditional lipid profiles to reduced glomerular filtration rate in H-type hypertension population of rural China. Ann Med. 2018;50:249–59.
47. Dursun M, Biesirgolu H, Otuncemar A, Ozbek E. Association between cardiometabolic index and erectile dysfunction: a new index for predicting cardiovascular disease. Kardisalj J Med Sci. 2016;32:620–3.
48. Amato M, Giordano C, Cilia M, Criscimanna A, Vitaire S, Midiri M, et al. Visceral adiposity index: a reliable indicator of visceral fat fraction associated with cardiometabolic risk. Diabetes Care. 2010;33:920–2.
49. Levey A, Stevens L, Schmid C, Zhang Y, Castro A, Feldman H, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
50. Stevens P, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30.
51. Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo J, et al. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.
52. Zannis V, Chroni A, Kriege M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med. 2006;84:F925–30.
53. Vaziri N, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1926–35.
54. Vaziri N, Deng G, Liang K, Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14:146–2.
55. Vaziri N, Liang K, Parks J. Down-regulation of hepatic lectin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001; 59:2192–6.
56. Mohamed-AlI V, Goodrick S, Bulmer K, Holly J, Yudkin J, Coppel S. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Phys. 1999;277:E971–5.
57. Drechsler C, Wanner C. The obesity paradox and the role of inflammation. J Am Soc Nephrol. 2016;27:1270–2.
58. KORN E. Clearing factor, a heparin-activated lipoprotein lipase. II. Substrate specificity and activation of coconut oil. J Biol Chem. 1955;215:15–26.
59. Vaziri N, Liang K, Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1926–35.
60. Vaziri N, Deng G, Liang K, Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14:146–2.
61. Vaziri N, Liang K, Parks J. Down-regulation of hepatic lectin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001; 59:2192–6.
62. Zannis V, Chroni A, Kriege M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med. 2006;84:926–34.
63. Ma L, Corsa B, Zhou J, Yang H, Li H, Tang Y, et al. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol. 2011;300:F1203–13.
64. Spoto B, Zoccalli C, Spleen IL-10, a key player in obesity-driven renal risk. Nephrol Dial Transplant. 2018;33:1061–4.